Corium International, Inc. Files For $50 Million IPO

Corium International, Inc. Files Registration Statement for Proposed Initial Public Offering

MENLO PARK, Calif., March 3, 2014 /PRNewswire/ -- Corium International, Inc., a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Corium. The number of shares to be sold and the price range for the proposed offering have not yet been determined. Corium plans to list its common stock on the NASDAQ Global Market under the ticker symbol "CORI."
Jefferies LLC and Leerink Partners LLC will act as joint book-running managers for the offering. Needham & Company, LLC and FBR Capital Markets & Co. will act as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at [email protected]; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, or by email at [email protected]

Investor and Media Contact:

Karen L. Bergman
[email protected]
(650) 575-1509

SOURCE Corium International, Inc.

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.